Catalyst price target raised to $25 from $22 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Catalyst Pharmaceuticals to $25 from $22 and keeps an Overweight rating on the shares. The firm views Catalyst’s successful year as a result of disciplined execution on its marketing strategy, as demonstrated primarily by enhanced Lambert-Eaton myasthenic syndrome awareness/education and patient access relative to pre-approval of FIRDAPSE, as well as recent business development with the FYCOMPA acquisition, the analyst tells investors in a research note.